vs
Side-by-side financial comparison of Inogen Inc (INGN) and MFA FINANCIAL, INC. (MFA). Click either name above to swap in a different company.
Inogen Inc is the larger business by last-quarter revenue ($68.6M vs $55.5M, roughly 1.2× MFA FINANCIAL, INC.). On growth, MFA FINANCIAL, INC. posted the faster year-over-year revenue change (9.2% vs 3.4%). Over the past eight quarters, MFA FINANCIAL, INC.'s revenue compounded faster (7.7% CAGR vs 4.2%).
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
INGN vs MFA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $68.6M | $55.5M |
| Net Profit | — | — |
| Gross Margin | 51.4% | — |
| Operating Margin | -13.6% | 97.9% |
| Net Margin | — | — |
| Revenue YoY | 3.4% | 9.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.26 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $68.6M | $55.5M | ||
| Q3 25 | $79.1M | $56.8M | ||
| Q2 25 | $79.2M | $61.3M | ||
| Q1 25 | $68.5M | $57.5M | ||
| Q4 24 | $66.3M | $50.8M | ||
| Q3 24 | $74.9M | $50.6M | ||
| Q2 24 | $74.4M | $53.5M | ||
| Q1 24 | $63.1M | $47.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.3M | $48.1M | ||
| Q2 25 | $-4.2M | $33.2M | ||
| Q1 25 | $-6.2M | $41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-6.0M | $48.2M | ||
| Q2 24 | $-5.6M | $41.9M | ||
| Q1 24 | $-14.6M | $23.2M |
| Q4 25 | 51.4% | — | ||
| Q3 25 | 52.2% | — | ||
| Q2 25 | 52.2% | — | ||
| Q1 25 | 53.1% | — | ||
| Q4 24 | 54.7% | — | ||
| Q3 24 | 55.2% | — | ||
| Q2 24 | 57.4% | — | ||
| Q1 24 | 54.5% | — |
| Q4 25 | -13.6% | 97.9% | ||
| Q3 25 | -9.0% | 84.5% | ||
| Q2 25 | -7.7% | 54.5% | ||
| Q1 25 | -11.2% | 70.0% | ||
| Q4 24 | -17.2% | 6.8% | ||
| Q3 24 | -10.4% | 98.2% | ||
| Q2 24 | -9.5% | 79.1% | ||
| Q1 24 | -25.8% | 50.7% |
| Q4 25 | — | — | ||
| Q3 25 | -6.7% | 84.7% | ||
| Q2 25 | -5.2% | 54.2% | ||
| Q1 25 | -9.0% | 71.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -8.0% | 95.2% | ||
| Q2 24 | -7.5% | 78.4% | ||
| Q1 24 | -23.1% | 48.5% |
| Q4 25 | $-0.26 | $0.43 | ||
| Q3 25 | $-0.20 | $0.35 | ||
| Q2 25 | $-0.15 | $0.21 | ||
| Q1 25 | $-0.25 | $0.31 | ||
| Q4 24 | $-0.41 | $-0.01 | ||
| Q3 24 | $-0.25 | $0.37 | ||
| Q2 24 | $-0.24 | $0.32 | ||
| Q1 24 | $-0.62 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.7M | $213.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $192.2M | $1.8B |
| Total Assets | $298.6M | $13.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.7M | $213.2M | ||
| Q3 25 | $106.5M | $305.2M | ||
| Q2 25 | $103.7M | $275.7M | ||
| Q1 25 | $118.9M | $253.7M | ||
| Q4 24 | $113.8M | $338.9M | ||
| Q3 24 | $105.7M | $305.6M | ||
| Q2 24 | $97.9M | $289.4M | ||
| Q1 24 | $107.4M | $306.3M |
| Q4 25 | $192.2M | $1.8B | ||
| Q3 25 | $197.2M | $1.8B | ||
| Q2 25 | $199.5M | $1.8B | ||
| Q1 25 | $198.0M | $1.8B | ||
| Q4 24 | $173.9M | $1.8B | ||
| Q3 24 | $185.4M | $1.9B | ||
| Q2 24 | $187.6M | $1.9B | ||
| Q1 24 | $191.9M | $1.9B |
| Q4 25 | $298.6M | $13.0B | ||
| Q3 25 | $307.0M | $12.1B | ||
| Q2 25 | $312.0M | $11.7B | ||
| Q1 25 | $308.4M | $11.5B | ||
| Q4 24 | $296.2M | $11.4B | ||
| Q3 24 | $306.2M | $11.2B | ||
| Q2 24 | $308.9M | $11.1B | ||
| Q1 24 | $315.6M | $10.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-943.0K | $76.2M |
| Free Cash FlowOCF − Capex | $-1.9M | — |
| FCF MarginFCF / Revenue | -2.8% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-943.0K | $76.2M | ||
| Q3 25 | $2.2M | $14.7M | ||
| Q2 25 | $4.3M | $38.5M | ||
| Q1 25 | $-16.8M | $-14.6M | ||
| Q4 24 | $-3.0M | $200.1M | ||
| Q3 24 | $7.0M | $-11.3M | ||
| Q2 24 | $6.7M | $46.5M | ||
| Q1 24 | $-4.7M | $53.5M |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $-17.1M | — | ||
| Q4 24 | $-3.3M | — | ||
| Q3 24 | $5.3M | — | ||
| Q2 24 | $6.6M | — | ||
| Q1 24 | $-6.1M | — |
| Q4 25 | -2.8% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | -24.9% | — | ||
| Q4 24 | -5.0% | — | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | -9.6% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | -0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.23× | ||
| Q2 24 | — | 1.11× | ||
| Q1 24 | — | 2.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INGN
| Other | $36.1M | 53% |
| Non Us | $32.5M | 47% |
MFA
Segment breakdown not available.